Company intelligence / Profile preview
Veta-Grand
- Ownership
- Private
- Development stage
- Other
Overview
Veta-Grand is a Russian biotechnology and pharmaceutical company specializing in the development and manufacture of photosensitizers for Photodynamic Therapy (PDT). The company's flagship product, Photoditazin (Fotoditazin), is a second-generation chlorin e6-based photosensitizer widely used in the treatment of various oncological conditions, including skin, lung, and bladder cancers. Beyond oncology, Veta-Grand focuses on applications in gynecology for the treatment of cervical intraepithelial neoplasia and in antimicrobial therapy. Based in Moscow, the company maintains strong collaborations with leading Russian clinical research institutions to advance the field of photomedicine and fluorescence diagnostics.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Veta-Grand.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Veta-Grand.